EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of ... ( TARRYTOWN N.Y. Dec. 4 /- EpiCept ...)

EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology

Date:12/3/2007

TARRYTOWN, N.Y., Dec. 4 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will be presenting new clinical data for Ceplene (histamine dihydrochloride) at the upcoming 49th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia from December 8-11, 2007. Ceplene is EpiCept's lead oncology product candidate under late stage review by the European Medicines Evaluation Agency (EMEA) for the remission maintenance treatment and prevention of relapse of patients with Acute Myeloid Leukemia (AML) in first remission.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

The results to be presented at the meeting include an analysis of the long-term outcomes of AML patients enrolled in the pivotal Phase III Ceplene study. The new data compares the effects of post-consolidation immunotherapy with histamine dihydrochloride (HDC) in conjunction with low dose interleukin- 2 (IL-2) on leukemia-free survival and overall survival compared to the current standard of care, which is no treatment, at five years post initiation of therapy.

The following poster presentations will be given by EpiCept on Sunday, December 9, 2007 from 9:00 a.m. to 8:00 p.m. Eastern Time at Hall B3 and B4 in the Georgia World Congress Center.

Poster # 36

Title: "Post-consolidation Immunotherapy with Histamine Dihydrochloride

and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival

and Overall Survival."

Session Name: Acute Myeloid Leukemias - Therapy, excluding

Transplantation.

Presenter: Mats L. Brune, et al; University of Goteborg, Goteborg,

Sweden.

Poster # 499

Title: "Histamine Dihydrochloride Maintains Cytoxic Effector Lymphocyte

Function and Viability under Conditions of Oxidative Stress."

'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets

Post Your Comments:

EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of ...( TARRYTOWN N.Y. Dec. 4 /- EpiCept ...),Health